Pharma Stocks Tumble on 100% Drug Tariff Threat

Trump administration targets branded drug imports while obesity pill competition heats up

Healthcare Market Overview

Healthcare stocks broadly declined after the Trump administration unveiled tariffs of up to 100% on branded and patented drug imports, set to take effect July 31 with full implementation in September. The policy targets companies that have not agreed to domestic drug price concessions or manufacturing investment commitments, sending shares of $ABBV, $MRNA, $AMGN, $LLY, and others lower. $UNH bucked the trend, gaining 1.2% to close at $277.26 as managed care names showed relative strength.

Big Pharma & Biotech

$MRK received European Union approval for KEYTRUDA in combination regimens for platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma that is PD-L1 positive, marking the first PD-1 inhibitor treatment for this patient group in the EU. The company also initiated a pivotal Phase 2b/3 trial of bispecific antibody MK-8748 (Tiespectus) in neovascular age-related macular degeneration. $REGN announced a strategic collaboration with TriNetX to access de-identified electronic health records of approximately 300 million patients, connecting large-scale genomic and proteomic data to support drug discovery and digital health solutions.

MedTech & Devices

$DXCM shares closed at $62.22, reflecting ongoing weakness with declines of 5.9% over seven days, 14.9% over 30 days, and 6.5% year-to-date as investors reassess valuation. The continuous glucose monitoring leader has experienced returns of -44.7% over three years and -34.2% over five years, signaling shifting market views on the company's growth prospects.

FDA & Regulation

The FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Amgen-distributed Tavneos (avacopan) in late March 2026, highlighting fresh safety concerns for the ANCA-associated vasculitis treatment. The Trump administration's new tariff policy offers drugmakers and countries that strike 'most favored nation' pricing deals or manufacturing commitments the opportunity to secure much lower levies or avoid tariffs entirely. More than a dozen major drugmakers have already struck pricing agreements with the White House.

Looking Ahead

The obesity drug market continues to intensify as Novo Nordisk released cross-trial data showing its oral Wegovy pill produces 3.2% greater weight loss than $LLY's newly FDA-approved Foundayo, with fewer adverse events and strong patient preference as Lilly prepares its U.S. launch. $AMGN announced a global collaboration with Zai Lab to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, expanding its oncology pipeline through external partnerships. Investors will closely monitor which additional pharma companies agree to pricing concessions ahead of the July 31 tariff implementation deadline.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy